SGHT Key Statistics, Chart & Performance
The current stock price of SGHT is 7.53 USD. In the past month the price decreased by -9.71%. In the past year, price increased by 131.69%.
SGHT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.29 | 219.41B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.95 | 207.41B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.35 | 145.84B | ||
| SYK | STRYKER CORP | 27.88 | 140.43B | ||
| BDX | BECTON DICKINSON AND CO | 14.23 | 58.56B | ||
| IDXX | IDEXX LABORATORIES INC | 56.49 | 56.88B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.91 | 49.08B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.21 | 40.16B | ||
| RMD | RESMED INC | 25.35 | 36.63B | ||
| DXCM | DEXCOM INC | 36.79 | 26.69B | ||
| PODD | INSULET CORP | 64.09 | 20.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.63 | 18.64B |
Related stock screener links
About SGHT
Company Profile
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company is headquartered in Menlo Park, California and currently employs 216 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Company Info
SIGHT SCIENCES INC
4040 Campbell Ave,, Suite 100
Menlo Park CALIFORNIA US
CEO: Paul Badawi
Employees: 216
Phone: 14158890550
SIGHT SCIENCES INC / SGHT FAQ
What does SGHT do?
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company is headquartered in Menlo Park, California and currently employs 216 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Can you provide the latest stock price for SIGHT SCIENCES INC?
The current stock price of SGHT is 7.53 USD. The price increased by 1.21% in the last trading session.
What is the dividend status of SIGHT SCIENCES INC?
SGHT does not pay a dividend.
What is the ChartMill technical and fundamental rating of SGHT stock?
SGHT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about SIGHT SCIENCES INC (SGHT) stock?
13 analysts have analysed SGHT and the average price target is 8.01 USD. This implies a price increase of 6.33% is expected in the next year compared to the current price of 7.53.
What is SIGHT SCIENCES INC worth?
SIGHT SCIENCES INC (SGHT) has a market capitalization of 398.11M USD. This makes SGHT a Small Cap stock.
Can you provide the ownership details for SGHT stock?
You can find the ownership structure of SIGHT SCIENCES INC (SGHT) on the Ownership tab.
SGHT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SGHT. When comparing the yearly performance of all stocks, SGHT is one of the better performing stocks in the market, outperforming 98.22% of all stocks.
SGHT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SGHT. While SGHT seems to be doing ok healthwise, there are quite some concerns on its profitability.
SGHT Financial Highlights
Over the last trailing twelve months SGHT reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 11.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.66% | ||
| ROE | -71.72% | ||
| Debt/Equity | 0.62 |
SGHT Forecast & Estimates
13 analysts have analysed SGHT and the average price target is 8.01 USD. This implies a price increase of 6.33% is expected in the next year compared to the current price of 7.53.
For the next year, analysts expect an EPS growth of 17.29% and a revenue growth -3.98% for SGHT